BACKGROUND:Treatment outcomes for multidrug-resistant Mycobacterium Tuberculosis (MDRTB) are generally poor compared to drug sensitive disease. We sought to estimate treatment outcomes and identify risk factors associated with poor outcomes in patients with MDRTB. METHODOLOGY/PRINCIPAL FINDINGS:We performed a systematic search (to December 2008) to identify trials describing outcomes of patients treated for MDRTB. We pooled appropriate data to estimate WHO-defined outcomes at the end of treatment and follow-up. Where appropriate, pooled covariates were analyzed to identify factors associated with worse outcomes. Among articles identified, 36 met our inclusion criteria, representing 31 treatment programmes from 21 countries. In a pooled anal...
Background & objectives: The increase in the burden of multidrug-resistant tuberculosis (MDR-TB) is ...
Background: This study was undertaken to analyze the clinical profile and treatment outcome in pulmo...
Background. According to World Health Organization (WHO) the final multidrug resistant tuberculosis ...
(MDRTB) are generally poor compared to drug sensitive disease. We sought to estimate treatment outc...
Item does not contain fulltextBACKGROUND: Treatment outcomes for multidrug-resistant tuberculosis re...
Background: Anti-tuberculosis drug resistance is a major public health problem that threatens the pr...
Background: There is increasing evidence that community-based treatment of drug res...
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate...
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate...
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate...
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has general...
Objective The consistent emerging of multidrug-resistant tuberculosis (MDR-TB) cases are increasin...
Background. The treatment of extensively drug-resistant tuberculosis (XDR TB) presents a major chall...
RATIONALE: Few large-scale studies have investigated multidrug-resistant tuberculosis (MDR-TB) treat...
Rationale: Few large-scale studies have investigated multidrug-resistant tuberculosis (MDR-TB) treat...
Background & objectives: The increase in the burden of multidrug-resistant tuberculosis (MDR-TB) is ...
Background: This study was undertaken to analyze the clinical profile and treatment outcome in pulmo...
Background. According to World Health Organization (WHO) the final multidrug resistant tuberculosis ...
(MDRTB) are generally poor compared to drug sensitive disease. We sought to estimate treatment outc...
Item does not contain fulltextBACKGROUND: Treatment outcomes for multidrug-resistant tuberculosis re...
Background: Anti-tuberculosis drug resistance is a major public health problem that threatens the pr...
Background: There is increasing evidence that community-based treatment of drug res...
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate...
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate...
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate...
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has general...
Objective The consistent emerging of multidrug-resistant tuberculosis (MDR-TB) cases are increasin...
Background. The treatment of extensively drug-resistant tuberculosis (XDR TB) presents a major chall...
RATIONALE: Few large-scale studies have investigated multidrug-resistant tuberculosis (MDR-TB) treat...
Rationale: Few large-scale studies have investigated multidrug-resistant tuberculosis (MDR-TB) treat...
Background & objectives: The increase in the burden of multidrug-resistant tuberculosis (MDR-TB) is ...
Background: This study was undertaken to analyze the clinical profile and treatment outcome in pulmo...
Background. According to World Health Organization (WHO) the final multidrug resistant tuberculosis ...